Reports and Briefs on Therapy Area in China

Published within

« | 1 | 2 | 3 | 4 | » »|

Type Product title / description Pub Price
Report
Report

Autoimmune Market Access in China – New biologic therapies drive future growth

Despite ongoing competition from biosimilars, branded biologics will continue to drive the Chinese autoimmune market, with two new brands, Enbrel (etanercept; Pfizer) and Humira (adalimumab; Abbott), having been approved and launched in 2010.

Published By Datamonitor
14 Sep 2011 $5700
Buy
Report
Report

Cardiovascular and Metabolic Diseases Market Access in China – Managing challenges to harness growing commercial potential

The large number of Chinese CV & metabolic diseases patients brings significant commercial opportunities for Pharma. Plans to expand insurance coverage and improve healthcare infrastructure will enhance therapy access, boosting the market potential.

Published By Datamonitor
09 Dec 2011 $5700
Buy
Report
Report

CNS Market Access in China - Investment in mental health services offers growth opportunities for psychiatry players

This report examines the CNS market in China. It reviews the epidemiology and treatment of key conditions. It also provides analysis of the strengths, weaknesses, opportunities and threats of the market and strategies for market penetration.

Published By Datamonitor
05 Jul 2011 $5700
Buy
Report
Report

Commercial Insight: Antidiabetics in China - Rising patient numbers and novel products drive the future market

Discussion of the Chinese diabetes market including epidemiology, market drivers, and strategic analysis of key players. Assessment of marketed and pipeline products. Commercial forecast of market size and product sales and volumes to 2019.

Published By Datamonitor
21 Feb 2011 $5700
Buy
Report
Report

Commercial Insight: Hepatitis B in China

Discussion of the Chinese hepatitis B market including epidemiology, market drivers, and strategic analysis of key players. Assessment of marketed and pipeline products. Commercial forecast of market size and product sales and volumes to 2019.

Published By Datamonitor
17 Feb 2011 $5700
Buy
Report
Report

Commercial Insight: Osteoporosis - Market players maximize revenue growth before the next challenging phase

Comprehensive analysis of the current and future osteoporosis drug market, with country-specific forecasts to 2019 of marketed, generic, and key pipeline drugs in the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK).

Published By Datamonitor
21 Jul 2010 $15200
Buy
Report
Report

Epidemiology of Hepatitis C in China

Urban migration and injection drug use patterns will continue to influence hepatitis C virus prevalence rates

Published By Datamonitor
03 Jan 2013 $4500
Buy
Report
Report

Epidemiology of Hepatocellular Cancer in China

The size of HCC patient population in China provides a lucrative market for anti-cancer drugs. This epidemiologic analysis uses historical cancer incidence data to estimate and forecast HCC patient populations in China between 2012 and 2030.

Published By Datamonitor
25 Apr 2013 $3500
Buy
Report
Report

Epidemiology: Asthma in China – Aging population and rising urbanization increase asthma prevalence

Overview of asthma prevalence in China and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10-year prevalent case forecast, and key patient segments across the seven major markets.

Published By Datamonitor
28 Jun 2012 $7600
Buy
Report
Report

Epidemiology: Breast Cancer in China – Increasing risk factors and aging population drive growth in incidence

Overview of breast cancer in China, definition, and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10-year incident and prevalent case forecast, and key patient segments across China.

Published By Datamonitor
16 Mar 2012 $5700
Buy

« | 1 | 2 | 3 | 4 | » »|

No help is available.